Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar
CAMBRIDGE, Mass. , July 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the jury in the District Court for the District of Massachusetts in Boston has issued its verdict finding that the Company's U.S. Patent No.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Second Quarter 2017 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , July 19, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2017 before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , June 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the timing of regulatory
View HTML
Toggle Summary Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer
CAMBRIDGE, Mass. , June 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Santiago Arroyo , M.D., Ph.D.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , May 10, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results
--Company reports Glatopa ® 20 mg product revenues of $23 million , a 58% increase over the same period in 2016-- --Ended the first quarter with a strong cash position of $434 million -- CAMBRIDGE, Mass. , May 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference
CAMBRIDGE, Mass. , April 26, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Deutsche Bank 42nd Annual Health Care Conference .
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , April 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2017 before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference
CAMBRIDGE, Mass. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference .
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
CAMBRIDGE, Mass. , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2016 . For the fourth quarter of 2016, the Company reported total revenues of $34.2 million , including $15.8
View HTML